Inogen (INGN) vs RxSight (RXST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Inogen (INGN) has outperformed RxSight (RXST) over the past year, losing 32.2% versus a loss of 42.0%. Over five years, RXST leads with a -64.6% price change compared with -85.7% for INGN. RxSight is the larger company by market cap ($199.6 million vs $154.5 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INGN | RXST |
|---|---|---|
| Share price | $5.82 | $4.80 |
| Market cap | $154.45M | $199.65M |
| 1-day change | +0.87% | +3.23% |
| YTD return | -13.39% | -53.93% |
| 1-year return | -32.25% | -42.03% |
| 5-year return | -85.74% | -64.60% |
| EPS (TTM) | $-0.92 | $-1.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.13 | $13.22 |
| 52-week low | $5.05 | $4.48 |
| Distance from 52-week high | -36.25% | -63.69% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +106.19% | +57.71% |
| Average volume | 290.91K | 861.88K |
| Shares outstanding | 26.54M | 41.59M |
| Employees | 753 | 461 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Inogen
INGN stock →Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Healthcare · Medical Devices · 753 employees
About RxSight
RXST stock →RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Healthcare · Medical Devices · 461 employees
INGN vs RXST FAQ
Which is bigger, Inogen or RxSight?
RxSight (RXST) is larger, with a market capitalization of $199.65M compared with $154.45M for Inogen (INGN).
Which stock has performed better over the past year, INGN or RXST?
INGN returned -32.25% over the past 12 months, compared with -42.03% for RXST (price return, excluding dividends). Past performance does not predict future results.
Are Inogen and RxSight in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.